HAYWARD, Calif .– (BUSINESS WIRE) – Dec. July 2021–
RefleXion Medical, Inc., a therapeutic oncology company pioneering bio-guided radiation therapy * (BgRT) as a new modality for treating all stages of cancer, today announced the sale of its RefleXion ™ X1 device to the Center for Cancer and Blood Disorders, a freestanding cancer treatment center with 15 locations across North Texas.
This press release contains multimedia. View the full version here: https://www.businesswire.com/news/home/20210721005043/en/
RefleXion Medical announces the sale of its X1 device to the Center for Cancer and Blood Disorders in Texas. (Photo: Business Wire)
“We are thrilled to bring the promise of bio-guided radiation therapy to the Dallas-Fort Worth Metroplex,” said Barry Russo, CEO of the Center for Cancer and Blood Disorders. “We have a long history of bringing our patients the latest advances in cancer therapies, clinical trials, and cancer research, and BgRT continues that convention. The multimodality of the X1 will ultimately enable us to offer advanced radiation therapy for all stages of solid tumor cancers, even for cancers for which this has not traditionally been possible. “
The RefleXion X1 device is for clinical use in stereotactic body radiation therapy (SBRT), stereotactic radiation surgery (SRS), intensity modulated radiation therapy (IMRT), and the forms of conventional radiation therapy indicated for early cancer or palliative relief of symptoms of later stage cancer. BgRT, which is currently in development, is designed to treat both early and late-stage cancer.
BgRT uses biological emissions from a patient’s cancer cells, generated by the injection of a small amount of a target molecule that carries a positron-emitting radioisotope known as a PET tracer, to guide radiation therapy. When the PET tracer binds to the tumor cells, it creates emissions that signal the location of the cancer. The RefleXion X1 device detects these emissions using PET detectors and reacts in real time to direct radiation therapy to and destroy any tumor, even if the tumor is moving.
“We are delighted with the commitment and enthusiasm of the Center for Cancer and Blood Disorders clinicians for our RefleXion X1 platform,” said Todd Powell, President and CEO of RefleXion. “This sale extends our commercial momentum to the southern United States, a large and growing market known for leveraging new technologies that enable cutting-edge patient care.”
Installation of the RefleXion X1 machine, which will be located on the main Fort Worth campus, is slated to begin in early 2022.
RefleXion is a privately held, commercial stage company developing the first biologically guided radiation therapy system, a significant change in strategy from single tumor therapy to the ability to treat multiple tumors in one day in the same treatment session for metastatic cancer. BgRT contains positron emission tomography (PET) imaging data so that tumors can continuously signal their position. The BgRT technology will synchronize this data with the linear accelerator to direct radiation therapy to tumors with a latency of less than a second.
* RefleXion ™ X1 is approved for SBRT / SRS / IMRT. BgRT is restricted to investigational use under US law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005043/en/
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: ONCOLOGY HEALTH MEDICAL DEVICES HOSPITAL RADIOLOGY PHARMACEUTICAL BIOTECHNOLOGY
Copyright Business Wire 2021.
PUB: 07/21/2021 10:00 am / DISC: 07/21/2021 10:02 am
Copyright Business Wire 2021.